Chasing Down the Triple-negative Myeloproliferative Neoplasms: Implications for Molecular Diagnostics

Overview

Journal JAKSTAT

Date 2017 Feb 2

PMID 28144498

Citations 8

Authors

Stephen E Langabeer

Affiliations

Soon will be listed here.

Abstract

The majority of patients with classical myeloproliferative neoplasms (MPN) of polycythemia vera, essential thrombocythemia, and primary myelofibrosis harbor distinct disease-driving mutations within the , , or genes. The term triple-negative has been recently applied to those MPN without evidence of these consistent mutations, prompting whole or targeted exome sequencing approaches to determine the driver mutational status of this subgroup. These strategies have identified numerous novel mutations that occur in alternative exons of both and , the majority of which result in functional activation. Current molecular diagnostic approaches may possess insufficient coverage to detect these alternative mutations, prompting further consideration of targeted exon sequencing into routine diagnostic practice. How to incorporate these illuminating findings into the expanding molecular diagnostic algorithm for MPN requires continual attention.

Citing Articles

Deepening Our Understanding of the Factors Affecting Landscape of Myeloproliferative Neoplasms: What Do We Know about Them?.

Morales M, Ferrer-Marin F Cancers (Basel). 2023; 15(4).

PMID: 36831689 PMC: 9954305. DOI: 10.3390/cancers15041348.

Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.

Kalmer M, Pannen K, Lemanzyk R, Wirths C, Baumeister J, Maurer A Ann Hematol. 2022; 101(12):2655-2663.

PMID: 36269400 PMC: 9646600. DOI: 10.1007/s00277-022-05000-9.

Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression.

Carnaz Simoes A, Holmstrom M, Aehnlich P, Rahbech A, Radziwon-Balicka A, Zamora C Front Immunol. 2022; 13:866610.

PMID: 35603202 PMC: 9120544. DOI: 10.3389/fimmu.2022.866610.

Is It Possible to Predict Clonal Thrombocytosis in Triple-Negative Patients with Isolated Thrombocytosis Based Only on Clinical or Blood Findings?.

Belcic Mikic T, Vratanar B, Pajic T, Anzej Doma S, Debeljak N, Zupan I J Clin Med. 2021; 10(24).

PMID: 34945099 PMC: 8706709. DOI: 10.3390/jcm10245803.

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.

Belcic Mikic T, Pajic T, Zver S, Sever M Int J Mol Sci. 2021; 22(7).

PMID: 33806036 PMC: 8038093. DOI: 10.3390/ijms22073371.

References

Gong J, Cook J, Greiner T, Hedvat C, Hill C, Lim M . Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology. J Mol Diagn. 2013; 15(6):733-44. DOI: 10.1016/j.jmoldx.2013.07.002. View

Langabeer S, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K . Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol. 2015; 95(4):270-9. DOI: 10.1111/ejh.12578. View

Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Burkle D . Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica. 2008; 94(1):141-4. PMC: 2625421. DOI: 10.3324/haematol.13224. View

Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour J, Ianotto J . Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2015; 127(3):333-42. DOI: 10.1182/blood-2015-07-661983. View

Tefferi A, Guglielmelli P, Larson D, Finke C, Wassie E, Pieri L . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124(16):2507-13. PMC: 4199952. DOI: 10.1182/blood-2014-05-579136. View

Milosevic Feenstra J, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I . Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2015; 127(3):325-32. PMC: 4752213. DOI: 10.1182/blood-2015-07-661835. View

Nelson N, Marcogliese A, Bergstrom K, Scheurer M, Mahoney D, Bertuch A . Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis. Pediatr Blood Cancer. 2016; 63(8):1484-7. PMC: 4916014. DOI: 10.1002/pbc.26032. View

Schnittger S, Bacher U, Kern W, Schroder M, Haferlach T, Schoch C . Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia. 2006; 20(12):2195-7. DOI: 10.1038/sj.leu.2404325. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

10.

Magor G, Tallack M, Klose N, Taylor D, Korbie D, Mollee P . Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation. J Mol Diagn. 2016; 18(5):707-718. DOI: 10.1016/j.jmoldx.2016.05.006. View

11.

Randi M, Geranio G, Bertozzi I, Micalizzi C, Ramenghi U, Tucci F . Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort. Br J Haematol. 2015; 169(4):584-9. DOI: 10.1111/bjh.13329. View

12.

Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau J . JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia. 2010; 24(5):1069-73. DOI: 10.1038/leu.2010.23. View

13.

Nangalia J, Grinfeld J, Green A . Pathogenesis of Myeloproliferative Disorders. Annu Rev Pathol. 2016; 11:101-26. DOI: 10.1146/annurev-pathol-012615-044454. View

14.

Hermouet S, Bigot-Corbel E, Gardie B . Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators Inflamm. 2015; 2015:145293. PMC: 4619950. DOI: 10.1155/2015/145293. View

15.

Angona A, Fernandez-Rodriguez C, Alvarez-Larran A, Camacho L, Longaron R, Torres E . Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing. Blood Cancer J. 2016; 6(8):e463. PMC: 5022184. DOI: 10.1038/bcj.2016.75. View

16.

Swierczek S, Lima L, Tashi T, Kim S, Gregg X, Prchal J . Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia. 2015; 29(12):2432-4. PMC: 5083033. DOI: 10.1038/leu.2015.249. View

17.

Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P . New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008; 22(8):1557-66. DOI: 10.1038/leu.2008.137. View

18.

Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T . Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol. 2016; 175(3):419-426. DOI: 10.1111/bjh.14269. View

19.

Hussein K, Percy M, McMullin M, Schwarz J, Schnittger S, Porret N . Clinical utility gene card for: hereditary thrombocythemia. Eur J Hum Genet. 2013; 22(2). PMC: 3895637. DOI: 10.1038/ejhg.2013.117. View

20.

Kirschner M, Schemionek M, Schubert C, Chatain N, Sontag S, Isfort S . Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing. PLoS One. 2015; 10(4):e0123476. PMC: 4404337. DOI: 10.1371/journal.pone.0123476. View